Aurinia Pharmaceuticals’ collaboration partner Otsuka Pharmaceutical has submitted a new drug application (NDA) to the Japanese Ministry of Health, Labour and Welfare for voclosporin to treat lupus nephritis (LN).
Mithra Pharmaceuticals has entered into a license and supply agreement with Searchlight Pharma for the Canadian rights to Donesta.
Aldena Therapeutics has selected PCI Pharma Services (PCI) for manufacturing and distributing of ALD-102, an investigational treatment for dermatological diseases.
Y.S.P. Industries has entered into an exclusive licensing agreement to develop and market TaiGen Biopharmaceuticals Holdings’ (TaiGen) new drug in Malaysia and Singapore.
BridgeBio Pharma has entered into a strategic partnership with National Resilience (Resilience) for the manufacturing and advancement of two investigational gene therapies, BBP-812 and BBP-631.
Cambrex has concluded the expansion of capacity at its small molecule active pharmaceutical ingredient (API) manufacturing facility in High Point, North Carolina, US.
Indian pharmaceutical firm Lupin has entered into an agreement to acquire five brands along with associated trademark rights from the units of Menarini -- A. Menarini India Private Limited and A. Menarini Asia-Pacific Holdings.
WuXi XDC has launched new commercial Good Manufacturing Practices (GMP) facilities in Wuxi, Jiangsu Province, China.
Novo Nordisk has launched Wegovy (semaglutide injection) as an adjunctive treatment for obese patients in the UK.
TheracosBio has announced the commercial availability of Brenzavvy (bexagliflozin) oral tablet for the treatment of adults with type 2 diabetes by prescription through the Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.